**FDA Warns Against Unapproved Stem Cell Treatments for Autism Amid Growing Concerns**
:max_bytes(150000):strip_icc():format(jpeg)/young-boy-in-hospital-062325-5077f374173945c5a6140676bb242afe.jpg)
In recent months, there has been a worrying rise in the number of clinics across the United States offering unapproved stem cell treatments for autism. With some families investing upwards of £15,000 per session, the ramifications of these therapies are concerning health experts and regulatory authorities alike. The Food and Drug Administration (FDA) has issued warnings about the potential dangers of these treatments, which it describes as lacking scientific validation.
Reports indicate that children as young as 18 months have undergone such procedures, which typically involve sedation with ketamine before being administered intravenous doses of stem cells derived from umbilical cords. This trend has gained traction following support from Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services. His endorsement has led many desperate families to seek these unproven therapies, believing they may alleviate the challenges posed by autism.
Among those seeking alternatives is Christy Holdren from Florida, whose eight-year-old son, Landyn, is nonverbal and on the autism spectrum. Holdren paid $12,500 for an unapproved treatment in October 2025, hoping to find relief for her son, who often exhibits distressing self-harming behaviours. Following the treatment, she noted some minor improvements; for instance, Landyn seemed to engage her gaze more frequently and tolerated haircuts. However, she recently reported an escalation in his aggressive behaviour and is contemplating another stem cell injection later this month.
Experts in the field are alarmed by the proliferation of such treatments. Arnold Kriegstein, a professor of neurology at the University of California, San Francisco, has been vocal about the exploitation of vulnerable families seeking answers. He described the situation as “completely bogus,” warning that the continued promotion of these procedures without concrete scientific backing can lead to dangerous consequences for those involved.
Kennedy’s stance on stem cell research, including unproven treatments, has drawn significant criticism. At a Senate confirmation hearing in October 2024, he condemned the FDA’s regulatory oversight as a “war on public health,” expressing his commitment to supporting innovations in stem cell and gene therapies. His remarks resonated with some who believe the FDA has hindered access to potentially beneficial treatments, though critics argue such claims overlook the essential safeguards that the FDA is mandated to enforce.
Despite ongoing advocacy for greater access to experimental treatments, the FDA maintains that its primary role is to ensure the safety and efficacy of medical interventions. Currently, the agency allows only specific stem cell therapies for certain blood and immune disorders but has historically cracked down on clinics that offer unapproved treatments for a myriad of conditions, including autism.
The FDA has routinely cautioned against the dangers associated with unapproved regenerative medicine products. It highlights the potential for severe complications, including infections, tumour formation, and blindness. The agency has emphasised that families seeking these therapies may be misled, as many of the products available in the market are illegal.
Moreover, experts point out that there is a troubling trend of declining enforcement within the FDA under Kennedy’s leadership. Paul Knoepfler, a stem cell biologist at UC Davis, remarked on the observed lack of regulatory action over recent months, raising concerns that the FDA may be loosening its grip on oversight of stem cell therapies.
Families, driven by the desire for solutions, often find themselves navigating a convoluted landscape of misinformation and unregulated practices. The risks associated with these unapproved treatments underscore a broader issue in healthcare, where vulnerable populations are targeted by providers peddling questionable medical interventions.
With expert consensus against the viability of these treatments, it becomes increasingly imperative for families to critically assess the information presented to them, seeking advice from qualified professionals who adhere to scientific rigour. As discussions surrounding the efficacy of stem cell treatments evolve, families are cautioned to remain vigilant and informed about the complexities surrounding autism and its treatment.
As the debate continues, the FDA’s role in protecting public health and ensuring that ethical standards are upheld will remain crucial in safeguarding children and their families from the dangers of unproven therapies. The ongoing challenge is to balance the quest for innovation in treatment with the necessity for stringent oversight and ethical responsibility in the medical community.